Kingdon Capital Management L.L.C. Invests $16.13 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Kingdon Capital Management L.L.C. bought a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXFree Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 746,293 shares of the company’s stock, valued at approximately $16,127,000. Syndax Pharmaceuticals accounts for about 2.0% of Kingdon Capital Management L.L.C.’s investment portfolio, making the stock its 14th largest holding. Kingdon Capital Management L.L.C. owned approximately 0.88% of Syndax Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of SNDX. Arizona State Retirement System boosted its position in shares of Syndax Pharmaceuticals by 5.3% in the fourth quarter. Arizona State Retirement System now owns 16,511 shares of the company’s stock worth $357,000 after buying an additional 835 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Syndax Pharmaceuticals by 3.6% in the 3rd quarter. New York State Common Retirement Fund now owns 30,825 shares of the company’s stock valued at $448,000 after purchasing an additional 1,080 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Syndax Pharmaceuticals by 9.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,126 shares of the company’s stock worth $305,000 after purchasing an additional 1,162 shares in the last quarter. CWM LLC boosted its holdings in shares of Syndax Pharmaceuticals by 415.3% during the fourth quarter. CWM LLC now owns 1,685 shares of the company’s stock worth $36,000 after purchasing an additional 1,358 shares during the period. Finally, Quadrant Capital Group LLC grew its stake in Syndax Pharmaceuticals by 158.3% in the fourth quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock valued at $53,000 after purchasing an additional 1,496 shares in the last quarter.

Insider Buying and Selling at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan acquired 1,250 shares of Syndax Pharmaceuticals stock in a transaction on Friday, June 14th. The shares were bought at an average price of $20.03 per share, with a total value of $25,037.50. Following the completion of the purchase, the chief financial officer now owns 52,623 shares in the company, valued at $1,054,038.69. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals Stock Performance

NASDAQ SNDX traded down $0.23 during trading on Monday, reaching $19.88. 781,070 shares of the company traded hands, compared to its average volume of 1,099,319. Syndax Pharmaceuticals, Inc. has a 1-year low of $11.22 and a 1-year high of $25.34. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -6.17 and a beta of 1.01. The stock’s 50 day moving average price is $20.82 and its two-hundred day moving average price is $21.37.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Free Report) last posted its earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.11. During the same period in the prior year, the company posted ($0.59) EPS. Equities research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on SNDX shares. Scotiabank lowered Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday. HC Wainwright reiterated a “buy” rating and issued a $41.00 target price on shares of Syndax Pharmaceuticals in a research note on Monday. Citigroup reduced their price objective on Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Stifel Nicolaus upped their target price on shares of Syndax Pharmaceuticals from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and issued a $34.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.42.

View Our Latest Stock Report on Syndax Pharmaceuticals

Syndax Pharmaceuticals Company Profile

(Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Further Reading

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.